Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation
What is Known and Objective Our previous report indicated that teicoplanin (TEIC) caused fewer adverse effects than vancomycin (VCM) in patients with febrile neutropenia (FN) receiving haematopoietic stem cell transplantation (HSCT). However, we observed breakthrough methicillin‐resistant‐Staphyloco...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2020-12, Vol.45 (6), p.1342-1348 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1348 |
|---|---|
| container_issue | 6 |
| container_start_page | 1342 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 45 |
| creator | Ohata, Koichi Kitagawa, Junichi Niwa, Takashi Takahashi‐Yamauchi, Tomoyo Harada, Saki Matsumoto, Takuro Nakamura, Nobuhiko Nakamura, Hiroshi Kanemura, Nobuhiro Shimizu, Masahito Suzuki, Akio |
| description | What is Known and Objective
Our previous report indicated that teicoplanin (TEIC) caused fewer adverse effects than vancomycin (VCM) in patients with febrile neutropenia (FN) receiving haematopoietic stem cell transplantation (HSCT). However, we observed breakthrough methicillin‐resistant‐Staphylococcus haemolyticus (MR‐S haemolyticus) infection during TEIC therapy in these patients. In this study, we sought to compare the incidence of breakthrough Gram‐positive cocci (GPC) infection during VCM and TEIC therapy in this population.
Methods
A single‐centre, retrospective cohort study was conducted. Patients who had received HSCT and were administered VCM (n = 19) or TEIC (n = 38) for FN from 1 September 2011 to 31 August 2019 were enrolled. We compared the incidence of breakthrough GPC infection between the VCM and TEIC groups.
Results
Breakthrough GPC infection during glycopeptide therapy in febrile neutropenic patients received HSCT was observed in three patients (7.9%) in the TEIC group but in none of patients (0%) in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility (TEIC MIC = 2‐8 μg/mL, VCM MIC = 2‐4 μg/mL) was isolated from blood cultures in all patients with breakthrough GPC infections. All breakthrough infections were cured by changing from TEIC to daptomycin (DAP).
What is New and Conclusion
The incidence of breakthrough GPC infection during glycopeptide therapy in febrile neutropenic HSCT patients was higher in the TEIC group than in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility was isolated from all patients with breakthrough GPC infection and successfully treated with DAP.
The incidence of breakthrough Gram‐positive cocci infection during glycopeptide therapy in febrile neutropenic patients who received hematopoietic stem cell transplantation was higher, albeit without significance, in the teicoplanin group than in the vancomycin group (7.9% vs 0%, P = .544). |
| doi_str_mv | 10.1111/jcpt.13215 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2423514067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2457962801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3705-852ae2820f2024517a9ec579a0bc76c18888c43368560d05f631bac3d87cfbe63</originalsourceid><addsrcrecordid>eNp9kU2OEzEQhS0EEmFgwwkssUFIPfinbXeWKGKGQSPBYli3nEr1xKHbNrY7o-w4AmfgaJwEN2HFgtqUSvpe1VM9Ql5ydslrvT1ALJdcCq4ekRWXWjXCcPaYrJjQ66Y1wjwlz3I-MMa0EXJFfm7CFG1yOXgaBrpNaL-WfQrz_Z5eJzv9-v4jhuyKOyKFAOCo8wNCcZXfzcn5e3q0HsJ0AufpMdOCDkIcra9j2WOy8VQlNNri0JdMEwK646LbW5xsCTE4LA5oLjhRwHGkJVmflxXFLneekyeDHTO--NsvyJer93ebD83tp-ubzbvbBqRhqumUsCg6wQbBRKu4sWsEZdaWbcFo4F0taKXUndJsx9SgJd9akLvOwLBFLS_I6_PemMK3GXPpJ5cXQ9ZjmHMvWiEVb-vjKvrqH_QQ5uSru0rVm1p0jFfqzZmCFHJOOPQxucmmU89Zv8TVL3H1f-KqMD_DD27E03_I_uPm891Z8xs8mpzf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2457962801</pqid></control><display><type>article</type><title>Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ohata, Koichi ; Kitagawa, Junichi ; Niwa, Takashi ; Takahashi‐Yamauchi, Tomoyo ; Harada, Saki ; Matsumoto, Takuro ; Nakamura, Nobuhiko ; Nakamura, Hiroshi ; Kanemura, Nobuhiro ; Shimizu, Masahito ; Suzuki, Akio</creator><creatorcontrib>Ohata, Koichi ; Kitagawa, Junichi ; Niwa, Takashi ; Takahashi‐Yamauchi, Tomoyo ; Harada, Saki ; Matsumoto, Takuro ; Nakamura, Nobuhiko ; Nakamura, Hiroshi ; Kanemura, Nobuhiro ; Shimizu, Masahito ; Suzuki, Akio</creatorcontrib><description>What is Known and Objective
Our previous report indicated that teicoplanin (TEIC) caused fewer adverse effects than vancomycin (VCM) in patients with febrile neutropenia (FN) receiving haematopoietic stem cell transplantation (HSCT). However, we observed breakthrough methicillin‐resistant‐Staphylococcus haemolyticus (MR‐S haemolyticus) infection during TEIC therapy in these patients. In this study, we sought to compare the incidence of breakthrough Gram‐positive cocci (GPC) infection during VCM and TEIC therapy in this population.
Methods
A single‐centre, retrospective cohort study was conducted. Patients who had received HSCT and were administered VCM (n = 19) or TEIC (n = 38) for FN from 1 September 2011 to 31 August 2019 were enrolled. We compared the incidence of breakthrough GPC infection between the VCM and TEIC groups.
Results
Breakthrough GPC infection during glycopeptide therapy in febrile neutropenic patients received HSCT was observed in three patients (7.9%) in the TEIC group but in none of patients (0%) in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility (TEIC MIC = 2‐8 μg/mL, VCM MIC = 2‐4 μg/mL) was isolated from blood cultures in all patients with breakthrough GPC infections. All breakthrough infections were cured by changing from TEIC to daptomycin (DAP).
What is New and Conclusion
The incidence of breakthrough GPC infection during glycopeptide therapy in febrile neutropenic HSCT patients was higher in the TEIC group than in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility was isolated from all patients with breakthrough GPC infection and successfully treated with DAP.
The incidence of breakthrough Gram‐positive cocci infection during glycopeptide therapy in febrile neutropenic patients who received hematopoietic stem cell transplantation was higher, albeit without significance, in the teicoplanin group than in the vancomycin group (7.9% vs 0%, P = .544).</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.13215</identifier><language>eng</language><publisher>Oxford: Hindawi Limited</publisher><subject>Antibiotics ; breakthrough infection ; Cocci ; Daptomycin ; Glycopeptides ; haematopoietic stem cell transplantation ; Hematopoietic stem cells ; Infections ; Methicillin ; methicillin‐resistant Staphylococcus haemolyticus ; Neutropenia ; Stem cell transplantation ; Stem cells ; Teicoplanin ; Vancomycin</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2020-12, Vol.45 (6), p.1342-1348</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3705-852ae2820f2024517a9ec579a0bc76c18888c43368560d05f631bac3d87cfbe63</citedby><cites>FETCH-LOGICAL-c3705-852ae2820f2024517a9ec579a0bc76c18888c43368560d05f631bac3d87cfbe63</cites><orcidid>0000-0001-8671-5856 ; 0000-0003-2106-2123 ; 0000-0002-4947-4341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.13215$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.13215$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27913,27914,45563,45564</link.rule.ids></links><search><creatorcontrib>Ohata, Koichi</creatorcontrib><creatorcontrib>Kitagawa, Junichi</creatorcontrib><creatorcontrib>Niwa, Takashi</creatorcontrib><creatorcontrib>Takahashi‐Yamauchi, Tomoyo</creatorcontrib><creatorcontrib>Harada, Saki</creatorcontrib><creatorcontrib>Matsumoto, Takuro</creatorcontrib><creatorcontrib>Nakamura, Nobuhiko</creatorcontrib><creatorcontrib>Nakamura, Hiroshi</creatorcontrib><creatorcontrib>Kanemura, Nobuhiro</creatorcontrib><creatorcontrib>Shimizu, Masahito</creatorcontrib><creatorcontrib>Suzuki, Akio</creatorcontrib><title>Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation</title><title>Journal of clinical pharmacy and therapeutics</title><description>What is Known and Objective
Our previous report indicated that teicoplanin (TEIC) caused fewer adverse effects than vancomycin (VCM) in patients with febrile neutropenia (FN) receiving haematopoietic stem cell transplantation (HSCT). However, we observed breakthrough methicillin‐resistant‐Staphylococcus haemolyticus (MR‐S haemolyticus) infection during TEIC therapy in these patients. In this study, we sought to compare the incidence of breakthrough Gram‐positive cocci (GPC) infection during VCM and TEIC therapy in this population.
Methods
A single‐centre, retrospective cohort study was conducted. Patients who had received HSCT and were administered VCM (n = 19) or TEIC (n = 38) for FN from 1 September 2011 to 31 August 2019 were enrolled. We compared the incidence of breakthrough GPC infection between the VCM and TEIC groups.
Results
Breakthrough GPC infection during glycopeptide therapy in febrile neutropenic patients received HSCT was observed in three patients (7.9%) in the TEIC group but in none of patients (0%) in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility (TEIC MIC = 2‐8 μg/mL, VCM MIC = 2‐4 μg/mL) was isolated from blood cultures in all patients with breakthrough GPC infections. All breakthrough infections were cured by changing from TEIC to daptomycin (DAP).
What is New and Conclusion
The incidence of breakthrough GPC infection during glycopeptide therapy in febrile neutropenic HSCT patients was higher in the TEIC group than in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility was isolated from all patients with breakthrough GPC infection and successfully treated with DAP.
The incidence of breakthrough Gram‐positive cocci infection during glycopeptide therapy in febrile neutropenic patients who received hematopoietic stem cell transplantation was higher, albeit without significance, in the teicoplanin group than in the vancomycin group (7.9% vs 0%, P = .544).</description><subject>Antibiotics</subject><subject>breakthrough infection</subject><subject>Cocci</subject><subject>Daptomycin</subject><subject>Glycopeptides</subject><subject>haematopoietic stem cell transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Infections</subject><subject>Methicillin</subject><subject>methicillin‐resistant Staphylococcus haemolyticus</subject><subject>Neutropenia</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Teicoplanin</subject><subject>Vancomycin</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kU2OEzEQhS0EEmFgwwkssUFIPfinbXeWKGKGQSPBYli3nEr1xKHbNrY7o-w4AmfgaJwEN2HFgtqUSvpe1VM9Ql5ydslrvT1ALJdcCq4ekRWXWjXCcPaYrJjQ66Y1wjwlz3I-MMa0EXJFfm7CFG1yOXgaBrpNaL-WfQrz_Z5eJzv9-v4jhuyKOyKFAOCo8wNCcZXfzcn5e3q0HsJ0AufpMdOCDkIcra9j2WOy8VQlNNri0JdMEwK646LbW5xsCTE4LA5oLjhRwHGkJVmflxXFLneekyeDHTO--NsvyJer93ebD83tp-ubzbvbBqRhqumUsCg6wQbBRKu4sWsEZdaWbcFo4F0taKXUndJsx9SgJd9akLvOwLBFLS_I6_PemMK3GXPpJ5cXQ9ZjmHMvWiEVb-vjKvrqH_QQ5uSru0rVm1p0jFfqzZmCFHJOOPQxucmmU89Zv8TVL3H1f-KqMD_DD27E03_I_uPm891Z8xs8mpzf</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Ohata, Koichi</creator><creator>Kitagawa, Junichi</creator><creator>Niwa, Takashi</creator><creator>Takahashi‐Yamauchi, Tomoyo</creator><creator>Harada, Saki</creator><creator>Matsumoto, Takuro</creator><creator>Nakamura, Nobuhiko</creator><creator>Nakamura, Hiroshi</creator><creator>Kanemura, Nobuhiro</creator><creator>Shimizu, Masahito</creator><creator>Suzuki, Akio</creator><general>Hindawi Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8671-5856</orcidid><orcidid>https://orcid.org/0000-0003-2106-2123</orcidid><orcidid>https://orcid.org/0000-0002-4947-4341</orcidid></search><sort><creationdate>202012</creationdate><title>Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation</title><author>Ohata, Koichi ; Kitagawa, Junichi ; Niwa, Takashi ; Takahashi‐Yamauchi, Tomoyo ; Harada, Saki ; Matsumoto, Takuro ; Nakamura, Nobuhiko ; Nakamura, Hiroshi ; Kanemura, Nobuhiro ; Shimizu, Masahito ; Suzuki, Akio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3705-852ae2820f2024517a9ec579a0bc76c18888c43368560d05f631bac3d87cfbe63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibiotics</topic><topic>breakthrough infection</topic><topic>Cocci</topic><topic>Daptomycin</topic><topic>Glycopeptides</topic><topic>haematopoietic stem cell transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Infections</topic><topic>Methicillin</topic><topic>methicillin‐resistant Staphylococcus haemolyticus</topic><topic>Neutropenia</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Teicoplanin</topic><topic>Vancomycin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohata, Koichi</creatorcontrib><creatorcontrib>Kitagawa, Junichi</creatorcontrib><creatorcontrib>Niwa, Takashi</creatorcontrib><creatorcontrib>Takahashi‐Yamauchi, Tomoyo</creatorcontrib><creatorcontrib>Harada, Saki</creatorcontrib><creatorcontrib>Matsumoto, Takuro</creatorcontrib><creatorcontrib>Nakamura, Nobuhiko</creatorcontrib><creatorcontrib>Nakamura, Hiroshi</creatorcontrib><creatorcontrib>Kanemura, Nobuhiro</creatorcontrib><creatorcontrib>Shimizu, Masahito</creatorcontrib><creatorcontrib>Suzuki, Akio</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohata, Koichi</au><au>Kitagawa, Junichi</au><au>Niwa, Takashi</au><au>Takahashi‐Yamauchi, Tomoyo</au><au>Harada, Saki</au><au>Matsumoto, Takuro</au><au>Nakamura, Nobuhiko</au><au>Nakamura, Hiroshi</au><au>Kanemura, Nobuhiro</au><au>Shimizu, Masahito</au><au>Suzuki, Akio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><date>2020-12</date><risdate>2020</risdate><volume>45</volume><issue>6</issue><spage>1342</spage><epage>1348</epage><pages>1342-1348</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>What is Known and Objective
Our previous report indicated that teicoplanin (TEIC) caused fewer adverse effects than vancomycin (VCM) in patients with febrile neutropenia (FN) receiving haematopoietic stem cell transplantation (HSCT). However, we observed breakthrough methicillin‐resistant‐Staphylococcus haemolyticus (MR‐S haemolyticus) infection during TEIC therapy in these patients. In this study, we sought to compare the incidence of breakthrough Gram‐positive cocci (GPC) infection during VCM and TEIC therapy in this population.
Methods
A single‐centre, retrospective cohort study was conducted. Patients who had received HSCT and were administered VCM (n = 19) or TEIC (n = 38) for FN from 1 September 2011 to 31 August 2019 were enrolled. We compared the incidence of breakthrough GPC infection between the VCM and TEIC groups.
Results
Breakthrough GPC infection during glycopeptide therapy in febrile neutropenic patients received HSCT was observed in three patients (7.9%) in the TEIC group but in none of patients (0%) in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility (TEIC MIC = 2‐8 μg/mL, VCM MIC = 2‐4 μg/mL) was isolated from blood cultures in all patients with breakthrough GPC infections. All breakthrough infections were cured by changing from TEIC to daptomycin (DAP).
What is New and Conclusion
The incidence of breakthrough GPC infection during glycopeptide therapy in febrile neutropenic HSCT patients was higher in the TEIC group than in the VCM group. MR‐S haemolyticus with low glycopeptide susceptibility was isolated from all patients with breakthrough GPC infection and successfully treated with DAP.
The incidence of breakthrough Gram‐positive cocci infection during glycopeptide therapy in febrile neutropenic patients who received hematopoietic stem cell transplantation was higher, albeit without significance, in the teicoplanin group than in the vancomycin group (7.9% vs 0%, P = .544).</abstract><cop>Oxford</cop><pub>Hindawi Limited</pub><doi>10.1111/jcpt.13215</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8671-5856</orcidid><orcidid>https://orcid.org/0000-0003-2106-2123</orcidid><orcidid>https://orcid.org/0000-0002-4947-4341</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2020-12, Vol.45 (6), p.1342-1348 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2423514067 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antibiotics breakthrough infection Cocci Daptomycin Glycopeptides haematopoietic stem cell transplantation Hematopoietic stem cells Infections Methicillin methicillin‐resistant Staphylococcus haemolyticus Neutropenia Stem cell transplantation Stem cells Teicoplanin Vancomycin |
| title | Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A03%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20breakthrough%20Gram%E2%80%90positive%20cocci%20infection%20during%20vancomycin%20vs%20teicoplanin%20therapy%20in%20patients%20receiving%20haematopoietic%20stem%20cell%20transplantation&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Ohata,%20Koichi&rft.date=2020-12&rft.volume=45&rft.issue=6&rft.spage=1342&rft.epage=1348&rft.pages=1342-1348&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1111/jcpt.13215&rft_dat=%3Cproquest_cross%3E2457962801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2457962801&rft_id=info:pmid/&rfr_iscdi=true |